Acura to Receive Royalties on Sale of Pfizer Drug
From Associated Press (October 17, 2011)
PALATINE, Ill. -- Acura Pharmaceuticals Inc. said Monday that it is eligible to receive tiered royalty payments from Pfizer Inc. on sales of the painkiller Oxecta, which uses Acura technology to discourage abuse of the drug.
Acura, based in Palatine, Ill., said it is eligible for tiered payments ranging from 5 percent to 25 percent of the drug's sales starting on the anniversary of the first commercial sale of Oxecta. Pfizer, the world's largest drugmaker, has informed Acura that it started its Oxecta commercialization plan, but Acura does not expect the first commercial sale to occur in 2011.
Oxecta is an immediate-release drug that contains oxycodone, the active ingredient in OxyContin. It was approved in the U.S. in June and uses Acura's Aversion technology to discourage abuse by crushing and inhaling them or dissolving them for injection.
If the drug is exposed to water or alcohol, the oxycodone becomes trapped in a gel mixture, making it difficult to get into a needle. If inhaled, it creates a burning, irritating sensation in the nose.
Acura said in July it received a $20 million payment from Pfizer following Oxecta's approval.
Posted: October 2011